Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication.

Tinkhauser G
Pogosyan A
Tan H
Herz DM
Kühn AA
Brown P

Here, we show that pathological brain waves tend to come in long bursts in people with Parkinson’s disease, and that a burst at one site in the brain circuits controlling movement is likely to be associated with bursts elsewhere in the movement circuits. The duration and spread of these bursts is governed by dopamine, a chemical messenger that is deficient in Parkinson’s.

Video Abstract
Scientific Abstract

Exaggerated basal ganglia beta activity (13-35 Hz) is commonly found in patients with Parkinson's disease and can be suppressed by dopaminergic medication, with the degree of suppression being correlated with the improvement in motor symptoms. Importantly, beta activity is not continuously elevated, but fluctuates to give beta bursts. The percentage number of longer beta bursts in a given interval is positively correlated with clinical impairment in Parkinson's disease patients. Here we determine whether the characteristics of beta bursts are dependent on dopaminergic state. Local field potentials were recorded from the subthalamic nucleus of eight Parkinson's disease patients during temporary lead externalization during surgery for deep brain stimulation. The recordings took place with the patient quietly seated following overnight withdrawal of levodopa and after administration of levodopa. Beta bursts were defined by applying a common amplitude threshold and burst characteristics were compared between the two drug conditions. The amplitude of beta bursts, indicative of the degree of local neural synchronization, progressively increased with burst duration. Treatment with levodopa limited this evolution leading to a relative increase of shorter, lower amplitude bursts. Synchronization, however, was not limited to local neural populations during bursts, but also, when such bursts were cotemporaneous across the hemispheres, was evidenced by bilateral phase synchronization. The probability of beta bursts and the proportion of cotemporaneous bursts were reduced by levodopa. The percentage number of longer beta bursts in a given interval was positively related to motor impairment, while the opposite was true for the percentage number of short duration beta bursts. Importantly, the decrease in burst duration was also correlated with the motor improvement. In conclusion, we demonstrate that long duration beta bursts are associated with an increase in local and interhemispheric synchronization. This may compromise information coding capacity and thereby motor processing. Dopaminergic activity limits this uncontrolled beta synchronization by terminating long duration beta bursts, with positive consequences on network state and motor symptoms.

Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication.
When people with Parkinson’s are OFF levodopa, there are short- and long-duration bursts of beta-frequency oscillations (‘beta bursts’) in the subthalamic nucleus (STN), a part of basal ganglia circuits that control movement. When ON levodopa, shorter beta bursts are predominant. Long-duration beta bursts lead to a stronger phasic synchronization within the motor region of the STN, which is related to impaired movement in Parkinson’s disease. Beta bursts co-occur between hemispheres and are phase coupled, while these overlapping periods are more common OFF levodopa compared to ON levodopa.
Citation
2017. Brain, 140(11):2968-2981.
Related Content
Publication
Tinkhauser G, Torrecillos F, Duclos Y, Tan H, Pogosyan A, Fischer P, Carron R, Welter ML, Karachi C, Vandenberghe W, Nuttin B, Witjas T, Régis J, Azulay JP, Eusebio A, Brown P
2018. Neurobiol. Dis., 117(Sept):217-225.
Publication
Duchet B, Ghezzi F, Weerasinghe G, Tinkhauser G, Kühn AA, Brown P, Bick C, Bogacz R

2021. PLoS Comput Biol, 17(7)e1009116.

Publication
Tinkhauser G, Pogosyan A, Little S, Beudel M, Herz DM, Tan H, Brown P
2017. Brain, 140(4):1053-1067.
Publication
Khawaldeh S, Tinkhauser G, Shah SA, Petermann K, Debove I, Nguyen TAK, Nowacki A, Lachenmayer ML, Schuepbach M, Pollo C, Krack P, Woolrich M, Brown P
2020. Brain, 143(2):582-596.